Benjamin Burnett
Stock Analyst at Wells Fargo
(3.44)
# 935
Out of 5,156 analysts
98
Total ratings
47.3%
Success rate
5.76%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Benjamin Burnett
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMPH Amphastar Pharmaceuticals | Maintains: Overweight | $34 → $30 | $19.21 | +56.17% | 1 | Feb 27, 2026 | |
| ALKS Alkermes | Maintains: Overweight | $37 → $43 | $28.45 | +51.14% | 4 | Feb 26, 2026 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $193 → $202 | $164.49 | +22.80% | 4 | Feb 24, 2026 | |
| INSM Insmed | Maintains: Overweight | $234 → $208 | $143.13 | +45.32% | 2 | Feb 20, 2026 | |
| CNTA Centessa Pharmaceuticals | Maintains: Overweight | $30 → $35 | $26.09 | +34.15% | 3 | Nov 13, 2025 | |
| FATE Fate Therapeutics | Maintains: Hold | $5 → $3 | $1.33 | +125.56% | 3 | Mar 6, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Hold | $53 → $49 | $58.78 | -16.64% | 6 | Feb 13, 2025 | |
| ACLX Arcellx | Maintains: Buy | $83 → $122 | $114.50 | +6.55% | 5 | Oct 18, 2024 | |
| BEAM Beam Therapeutics | Maintains: Buy | $66 → $69 | $27.62 | +149.82% | 2 | Sep 11, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $63 → $68 | $35.08 | +93.84% | 7 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $4.4 → $4.6 | $2.50 | +84.00% | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $120 → $58 | $6.68 | +760.78% | 4 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $690 → $780 | $4.71 | +16,460.51% | 2 | Sep 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $44 | $35.87 | +22.67% | 1 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $20 | $11.35 | +76.21% | 2 | Mar 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $49 | $62.76 | -21.92% | 4 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $7 | $2.68 | +161.19% | 2 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $423 → $466 | $529.17 | -11.94% | 2 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $282 → $305 | $309.01 | -1.30% | 2 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $86 | $68.40 | +25.73% | 2 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $29 → $27 | $13.29 | +103.16% | 3 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $43 | $30.54 | +40.80% | 1 | Feb 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $65 → $45 | $22.61 | +99.03% | 1 | Dec 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $9 | $5.43 | +65.75% | 1 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $64 | $99.79 | -35.87% | 5 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $94 | $64.23 | +46.35% | 7 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $3.51 | +184.90% | 3 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $5.41 | +362.11% | 11 | Sep 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $330 → $360 | $69.15 | +420.61% | 2 | Jun 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $16 | $0.41 | +3,800.54% | 1 | Jan 6, 2021 |
Amphastar Pharmaceuticals
Feb 27, 2026
Maintains: Overweight
Price Target: $34 → $30
Current: $19.21
Upside: +56.17%
Alkermes
Feb 26, 2026
Maintains: Overweight
Price Target: $37 → $43
Current: $28.45
Upside: +51.14%
Axsome Therapeutics
Feb 24, 2026
Maintains: Overweight
Price Target: $193 → $202
Current: $164.49
Upside: +22.80%
Insmed
Feb 20, 2026
Maintains: Overweight
Price Target: $234 → $208
Current: $143.13
Upside: +45.32%
Centessa Pharmaceuticals
Nov 13, 2025
Maintains: Overweight
Price Target: $30 → $35
Current: $26.09
Upside: +34.15%
Fate Therapeutics
Mar 6, 2025
Maintains: Hold
Price Target: $5 → $3
Current: $1.33
Upside: +125.56%
CRISPR Therapeutics AG
Feb 13, 2025
Maintains: Hold
Price Target: $53 → $49
Current: $58.78
Upside: -16.64%
Arcellx
Oct 18, 2024
Maintains: Buy
Price Target: $83 → $122
Current: $114.50
Upside: +6.55%
Beam Therapeutics
Sep 11, 2024
Maintains: Buy
Price Target: $66 → $69
Current: $27.62
Upside: +149.82%
IDEAYA Biosciences
Sep 10, 2024
Maintains: Buy
Price Target: $63 → $68
Current: $35.08
Upside: +93.84%
May 14, 2024
Maintains: Hold
Price Target: $4.4 → $4.6
Current: $2.50
Upside: +84.00%
Apr 1, 2024
Maintains: Hold
Price Target: $120 → $58
Current: $6.68
Upside: +760.78%
Sep 10, 2021
Maintains: Buy
Price Target: $690 → $780
Current: $4.71
Upside: +16,460.51%
Mar 6, 2026
Maintains: Overweight
Price Target: $31 → $44
Current: $35.87
Upside: +22.67%
Mar 5, 2026
Maintains: Overweight
Price Target: $23 → $20
Current: $11.35
Upside: +76.21%
Feb 27, 2026
Maintains: Overweight
Price Target: $48 → $49
Current: $62.76
Upside: -21.92%
Feb 27, 2026
Maintains: Overweight
Price Target: $8 → $7
Current: $2.68
Upside: +161.19%
Feb 26, 2026
Maintains: Equal-Weight
Price Target: $423 → $466
Current: $529.17
Upside: -11.94%
Feb 20, 2026
Maintains: Equal-Weight
Price Target: $282 → $305
Current: $309.01
Upside: -1.30%
Feb 20, 2026
Maintains: Overweight
Price Target: $93 → $86
Current: $68.40
Upside: +25.73%
Feb 12, 2026
Maintains: Overweight
Price Target: $29 → $27
Current: $13.29
Upside: +103.16%
Feb 2, 2026
Initiates: Overweight
Price Target: $43
Current: $30.54
Upside: +40.80%
Dec 30, 2025
Maintains: Overweight
Price Target: $65 → $45
Current: $22.61
Upside: +99.03%
Dec 18, 2025
Maintains: Overweight
Price Target: $7 → $9
Current: $5.43
Upside: +65.75%
Apr 1, 2025
Maintains: Buy
Price Target: $78 → $64
Current: $99.79
Upside: -35.87%
Jan 24, 2025
Maintains: Buy
Price Target: $90 → $94
Current: $64.23
Upside: +46.35%
Jun 3, 2024
Maintains: Buy
Price Target: $7 → $10
Current: $3.51
Upside: +184.90%
Sep 15, 2023
Reiterates: Buy
Price Target: $25
Current: $5.41
Upside: +362.11%
Jun 28, 2021
Upgrades: Buy
Price Target: $330 → $360
Current: $69.15
Upside: +420.61%
Jan 6, 2021
Initiates: Hold
Price Target: $16
Current: $0.41
Upside: +3,800.54%